Does tumor-associated antigen TA90 immune complex assay predict recurrence and survival after surgical treatment of stage I-III melanoma?
The TA90-IC assay can accurately predict survival and detect the presence of subclinical disease after surgery for melanoma, which should be useful in selecting patients for adjuvant therapy. Because the TA90-IC assay detected recurrence on an average of 19 months sooner than did routine clinical and radiographic evaluation, it may allow more timely therapeutic interventions.
An association was found between the higher density of C. pneumoniae and fibrosis/calcification in stenotic aortic valves.